Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + vincristine + dexamethasone + doxorubicin + pegaspargase
- Development stage
- Unknown
- Lead developer
- Moffitt Cancer Center
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous, Intramuscular, Intrathecal
01
Overview
This investigational combination chemotherapy regimen, developed by the H. Lee Moffitt Cancer Center and Research Institute, consists of metformin added to a VPLD backbone (vincristine, dexamethasone, doxorubicin, and pegaspargase) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children and young adults. Metformin, traditionally an oral anti-diabetic medication, is utilized here for its ability to activate AMP-activated protein kinase (AMPK), which subsequently inhibits the unfolded protein response and induces endoplasmic reticulum stress in leukemia cells. The VPLD components provide standard cytotoxic effects through microtubule inhibition, glucocorticoid receptor activation, DNA intercalation, and asparagine depletion. A Phase I dose-escalation trial (NCT01324180) evaluated the safety and maximum tolerated dose of this combination, demonstrating it to be tolerable in heavily pretreated patients.
- Other names
- Metformin + VPLDMetformin with VPLD ChemotherapyMetformin with Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DNAGR (Glucocorticoid receptor)ND1 (Mitochondrial electron transport chain complex I)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on metformin + vincristine + dexamethasone + doxorubicin + pegaspargase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + vincristine + dexamethasone + doxorubicin + pegaspargase.